pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Jul 20·1 min read
save

UK regulator reports rise in drug approvals and new AI healthcare regulations

Jul 20, 2026·read at raps ↗RegulatoryPositive

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) released its 2025-2026 annual report to Parliament.

The agency highlighted that it approved more new medicines in the past year than in the previous year, marking an uptick in approvals.

It also noted a record removal of illegal drugs from circulation and outlined steps to advance regulation of artificial intelligence in healthcare.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Recon: BMS to construct AI supercomputer with Nividia; Tempus to acquire cancer diagnostic maker Personalis for $1.5B”

read at raps ↗
68 words · retrieved Jul 21
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology

related stories

  • Apr 27Erasca reports RAS cancer drug data after legal threat from RevolutionEndpoints
  • Apr 27Revolution Medicines threatens to sue Erasca over patent, efficacy claimsEndpoints
  • Apr 27Lilly to buy startup Ajax in bid for a better JAK drugBioPharma Dive
  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEndpoints